Cargando…

The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: a case report

BACKGROUND: Major depressive disorder (MDD) patients not responding to two or more different antidepressant treatments are currently considered to suffer from treatment resistant depression (TRD). Recently, intranasal esketamine has been approved by both the American Food and Drug Administration and...

Descripción completa

Detalles Bibliográficos
Autores principales: Matteo, Marcatili, Cristian, Pellicioli, Laura, Maggioni, Federico, Motta, Chiara, Redaelli, Lorenzo, Ghelfi, Michaela, Krivosova, Sibilla, Matteo, Roberto, Nava, Fabrizia, Colmegna, Antonios, Dakanalis, Alice, Caldiroli, Enrico, Capuzzi, Beatrice, Benatti, Francesca, Bertola, Nicoletta, Villa, Alberto, Piperno, Silvia, Ippolito, Massimo, Clerici
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444432/
https://www.ncbi.nlm.nih.gov/pubmed/34530843
http://dx.doi.org/10.1186/s12991-021-00365-z

Ejemplares similares